| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10062353 | HBV | ENSG00000160200.18 | protein_coding | CBS | No | No | 875 | P35520 |
| TVIS10062354 | HBV | ENSG00000160200.18 | protein_coding | CBS | No | No | 875 | P35520 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | CBS |
|---|---|
| DrugBank ID | DB00118 |
| Drug Name | Ademetionine |
| Target ID | BE0000323 |
| UniProt ID | P35520 |
| Regulation Type | activator |
| PubMed IDs | 11524006; 11559709; 12163655; 12269827 |
| Citations | Janosik M, Kery V, Gaustadnes M, Maclean KN, Kraus JP: Regulation of human cystathionine beta-synthase by S-adenosyl-L-methionine: evidence for two catalytically active conformations involving an autoinhibitory domain in the C-terminal region. Biochemistry. 2001 Sep 4;40(35):10625-33.@@Jacobs RL, Stead LM, Brosnan ME, Brosnan JT: Hyperglucagonemia in rats results in decreased plasma homocysteine and increased flux through the transsulfuration pathway in liver. J Biol Chem. 2001 Nov 23;276(47):43740-7. Epub 2001 Sep 14.@@Choumenkovitch SF, Selhub J, Bagley PJ, Maeda N, Nadeau MR, Smith DE, Choi SW: In the cystathionine beta-synthase knockout mouse, elevations in total plasma homocysteine increase tissue S-adenosylhomocysteine, but responses of S-adenosylmethionine and DNA methylation are tissue specific. J Nutr. 2002 Aug;132(8):2157-60.@@Evande R, Blom H, Boers GH, Banerjee R: Alleviation of intrasteric inhibition by the pathogenic activation domain mutation, D444N, in human cystathionine beta-synthase. Biochemistry. 2002 Oct 1;41(39):11832-7. |
| Groups | Approved; Investigational; Nutraceutical |
| Direct Classification | 5'-deoxy-5'-thionucleosides |
| SMILES | C[S+](CC[C@H](N)C([O-])=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=CN=C2N |
| Pathways | Phosphatidylcholine Biosynthesis PC(14:0/20:0); Phosphatidylcholine Biosynthesis PC(14:0/20:4(5Z,8Z,11Z,14Z)); Histidinemia; Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); Phosphatidylcholine Biosynthesis PC(14:0/20:5(5Z,8Z,11Z,14Z,17Z)); Phosphatidylcholine Biosynthesis PC(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)); Phosphatidylcholine Biosynthesis PC(14:0/20:2(11Z,14Z)); Tyrosine Metabolism; Disulfiram Action Pathway; Hyperprolinemia Type II; Methylhistidine Metabolism; Phosphatidylcholine Biosynthesis PC(14:0/15:0); Mercaptopurine Action Pathway; L-Arginine:Glycine Amidinotransferase Deficiency; Tyrosinemia Type I; Betaine Metabolism; Catecholamine Biosynthesis; Phenytoin (Antiarrhythmic) Action Pathway; Glycine and Serine Metabolism; Carnitine Synthesis; Phosphatidylcholine Biosynthesis PC(14:0/20:1(11Z)); Phosphatidylcholine Biosynthesis PC(14:0/22:5(4Z,7Z,10Z,13Z,16Z)); Hyperprolinemia Type I; Phosphatidylcholine Biosynthesis PC(14:0/18:2(9Z,12Z)); Phosphatidylcholine Biosynthesis PC(14:0/14:0); Histidine Metabolism; Cystathionine beta-Synthase Deficiency; Phosphatidylcholine Biosynthesis PC(14:0/16:1(9Z)); Arginine and Proline Metabolism; Sarcosine Oncometabolite Pathway |
| PharmGKB | PA164754994 |
| ChEMBL | CHEMBL1088977 |
